tuberculosis%20-%20pulmonary%20(pediatric)
TUBERCULOSIS - PULMONARY (PEDIATRIC)
Tuberculosis (TB) is caused by Mycobacterium tuberculosis, a gram-positive bacteria with slow growth rate that is enhanced by 6-8% carbon dioxide and temperature of 35-40ºC.
It is primarily transmitted through airborne route.
The number of tubercle bacilli expelled in the air by a TB infected person is directly related to their infectiousness.
TB transmission is rare in children <10 years old due to their inability to expectorate sputum and low TB bacilli load in their sputum.
TB infection in children is usually obtained from an infectious adolescent or adult depending on the closeness and length of contact and the index case's severity of lung involvement and infectiousness.

Monitoring

  • Each patient should be assessed by individual country’s National Tuberculosis Program at the following intervals:
    • 2 weeks after initiation of treatment
    • At the end of intensive phase
    • Every 2 months until the completion of treatment
  • Assessment during follow-up should include symptoms evaluation, treatment adherence assessment, adverse drug reactions & weight management
  • Perform sputum smear at the end of the 2nd month in patient who was smear positive at diagnosis
  • Repeat sputum exam should be performed at months 3 of therapy if sputum microscopy was positive at end of 2 months of treatment
    • Line probe assay or Xpert MTB/RIF for repeat exam is highly recommended
  • Since patients have a slow radiological response to treatment, repeat chest X-ray is not routinely required
  • Adverse drug reactions are less common compared in adults
  • For patients on Ethambutol, monthly evaluations of visual acuity & color discrimination are advised
Multi-Drug Resistant TB
  • Smear sputum microscopy & culture should be performed monthly until 3 consecutive negative results are obtained
  • Follow-up sputum culture should be performed every 2-3 months
Latent TB Infection
  • Healthcare practitioners who are managing patients undergoing Isoniazid-Rifapentine combination therapy weekly for 12 weeks or 3 HP should:
    • Monitor all patients, prior to & during therapy for the the presence of active TB disease
    • Educate patients, parents or caretakers regarding side effects & advise them to immediately seek consultation upon recognition of such reactions (eg rashes, decrease in blood pressure & platelet count, as well as those that are drug allergy-related)
    • Evaluate patients monthly for treatment compliance & presence of side effects
    • Request for liver function tests (LFTs) (or at least an aspartate aminotransferase [AST]) in patients with liver disease, HIV, juvenile alcoholics & drug-users using injection paraphernalias or those who are taking medications with interactions with other drugs
    • Facilitate blood tests for patients with abnormal results & those who are prone to hepatic disorder
      • 3 HP regimen should be discontinued if AST result is ≥5x the upper limit of normal (ULN) with no concomitant symptoms or ≥3x ULN with accompanying symptoms
    • In the presence of severe adverse reactions, discontinue 3HP regimen & manage side-effects
      • 3 HP may be continued if adverse reactions are mild-moderate & tolerable, with continuous monitoring of patient status
Drug-induced Hepatitis
  • Usually seen with Isoniazid, Rifampicin or Pyrazinamide therapy
  • Routine measurement of liver function tests is not usually necessary during therapy unless there is occurrence of jaundice, hepatomegaly or liver tenderness
Pyridoxine Deficiency
  • Commonly seen with Isoniazid therapy
  • Oral Pyridoxine is recommended in the following patients: Severely malnourished, HIV-infected, breastfeeding & pregnant adolescents
    • Supplementation of 5-10 mg/day is recommended
Orange-red Color Discoloration of Body Secretions
  • Associated with Rifampicin therapy
  • Benign in nature; reassure patient & parent

Prevention

Vaccination
Bacille-Calmette-Guerin (BCG)
  • Prevents life-threatening forms of tuberculosis (TB)
    • Has significant protective effect of about 50-80% for disseminated or miliary disease
  • Protective effect of BCG against pulmonary tuberculosis (PTB) is variable
  • Not recommended in immunocompromised patients
  • Multiple BCG vaccination is not recommended

Isoniazid Preventive Therapy

  • Reduces the risk of developing PTB by ~90% with good adherence
  • Recommended for patients <5 years of age presumed to have latent TB infection due to close contact with smear positive TB or human immunodeficiency virus (HIV) positive patient
  • Recommended Isoniazid dosage is 10 mg/kg/day PO once daily x 6 months
  • Follow-up is done every 2 months until treatment is complete
  • The addition of Rifampicin in Isoniazid monotherapy given for 3 months has been shown to be as effective as Isoniazid monotherapy
  • Isoniazid-Rifapentine combination, administered weekly for 12 weeks (3 HP) for the treatment of LTBI is approved for use in adults, patients 2-17 years of age, those who are afflicted with HIV & acquired immunodeficiency syndrome (AIDS) & are under ART which does not affect the actions of Rifapentine
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
In patients with type 2 diabetes, obesity may be protective against vision-threatening diabetic retinopathy, a recent Korea study has shown.
Roshini Claire Anthony, 4 days ago

Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.

07 Jun 2019
Low-dose aspirin therapy does not confer significant benefits to elderly patients with hypertension, but treatment appears to increase the risk of haemorrhagic events, suggest a Japan study.
4 days ago
The use of opioids may have limited long-term efficacy in the management of chronic noncancer pain, reports a new study.